BRP44 Antikörper

Produktnummer ABIN5564218

Der Maus Monoklonal anti-BRP44 Antikörper (Klon JCM-1) (ABIN5564218) detektiert spezifisch BRP44 in WB und IP. Dieser Antikörper reagiert spezifisch mit Proben aus Human und Maus.

Kurzübersicht für BRP44 Antikörper (ABIN5564218)

Target: BRP44 (Brain Protein 44 (BRP44))

Reaktivität: Human, Maus

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser BRP44 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunoprecipitation (IP)

Klon: JCM-1

Produktdetails anti-BRP44 Antikörper

Spezifität: Recognizes endogenous human and mouse MPC-2.

Kreuzreaktivität: Human, Maus

Immunogen: Peptide coupled to KLH.

Isotyp: IgG2b

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: Lot specific

Buffer: In PBS containing 25 % glycerol and 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C.

Haltbarkeit: 12 months

Details zu BRP44

Target: BRP44 (Brain Protein 44 (BRP44))

Andere Bezeichnung: MPC-2

Hintergrund: Pyruvate is the end-product of glycolysis, a major substrate for oxidative metabolism, and a branching point for glucose, lactate, fatty acid and amino acid synthesis. The mitochondrial enzymes that metabolize pyruvate are physically separated from cytosolic pyruvate pools and rely on a membrane transport system to shuttle pyruvate across the impermeable inner mitochondrial membrane (IMM). Two proteins, mitochondrial pyruvate carriers MPC-1 and MPC-2, form a heterooligomeric complex in the IMM to facilitate pyruvate transport. This step is required for mitochondrial pyruvate oxidation and carboxylation-critical reactions in intermediary metabolism that are dysregulated in several common metabolic diseases.

Pathways: Warburg Effekt